Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs

Diseases of the Esophagus

Volumn 14, Issue 3-4, 2001, Pages 197-201

  Ikeda, K ^a   Ishida, K ^a   Sato, N ^a   Koeda, K ^a   Aoki, K ^a   Kimura, Y ^a   Iwaya, T ^a   Ogasawara, S ^a   Iijima, S ^a   Nakamura, R ^a   Uesugi, N ^a   Maesawa, C ^a   Saito, K ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; METHYLPREDNISOLONE SODIUM SUCCINATE; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; BRONCHUS DISEASE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FATALITY; DRUG RESPONSE; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; FEMALE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THORAX CANCER; TRACHEA DISEASE; TREATMENT PLANNING; VASCULAR DISEASE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; RADIATION DOSAGE; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THORAX; TREATMENT OUTCOME;

EID: 0035717768     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2050.2001.00184.x     Document Type: Article

References (18)

1. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases
2. Surgical adjuvant treatment of esophageal carcinoma: A Japanese Esophageal Oncology Group experience
3. Pulmonary hypertension and polymorphonuclear leukocyte elastase after esophageal cancer operations
4. Combined modality therapy in the treatment of esophageal cancer
5. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese Esophageal Oncology Group Trial
6. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer
7. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study
8. Multimodality therapy for esophageal cancer
9. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037)
10. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese institutions trial
11. Problems in neoadjuvant chemoradiotherapy preceding surgery for advanced squamous cell carcinoma of the thoracic esophagus
12. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group
13. Parenteral versus enteral nutrition in cancer patients: Indications and practice
14. Mechanism for synergistic antitumor effect in the combination of 5- fluorouracil with cisplatin in vivo tumor models: From the view of biochemical modulation of 5-fluorouracil
15. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: A comparative study of three different schedules of cisplatin administration
16. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus
17. Effects of alanyl-glutamine on gut barrier function